Positive Results from a Phase I-II Trial of MDV3100, Perhaps a New Alternative Hormone Blockade Option

There has been some positive news coming out of the ASCO conference in Florida this past week. One of the most significant pieces of positive news deals with the results of a phase I-II trial of the drug known as MDV3100. Basically, more than half of subjects in the study with castration-resistant prostate cancer responded [...]